Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Novo Nordisk's star weight-loss oral medication enters its fifth week on the market, with over 38,000 prescriptions issued
According to Reuters on February 13, IQVIA data shows that the Danish pharmaceutical company Novo Nordisk (NVO.US)’s flagship weight loss drug Wegovy reached 38,220 prescriptions in its fifth week on the market.
Wegovy is a medication developed by Novo Nordisk for the treatment of obesity. Since its launch, prescriptions for the drug in the U.S. market have continued to grow, indicating strong market demand. As more doctors and patients become aware of and recognize Wegovy’s effectiveness, its prescriptions are expected to increase further.